Clinical Trials Logo

Clinical Trial Summary

Coronavirus 2019 (COVID-19) infection is associated with higher morbidity and mortality in adult patients on dialysis, and kidney transplant recipients (KTRs). Although children had lower morbidity and mortality, KTRs are more vulnerable than healthy children. It has already known that the general immune responses to vaccines, which are currently in practice (attenuated, conjugated, or recombinant) were lower than healthy controls in children and adolescents on dialysis and with a kidney transplantation. Uremic milieu and immunosuppressive drugs are the factors causing impaired immune response in this group of patients. The new mRNA vaccine technology is used worldwide including children and adolescents during the pandemic. Studies have demonstrated lower immune response to new SARS-CoV-2 mRNA vaccine in adult KTRs. However, there is limited data about vaccine-induced immune response in children and adolescent with renal replacement therapy. The aim of this study was to assess immune response to SARS-CoV-2 mRNA BNT162b2 and its clinical and laboratory correlates in children and adolescent KTRs. Humoral immune response was assessed by anti-SARS-CoV-2 immunoglobulin G (Anti-S IgG) and its clinical correlate neutralizing antibody (nAb). Cellular immune response was assessed with SARS-CoV-2 specific Interferon ɣ release assay (IGRA).


Clinical Trial Description

This is a prospective, multicenter case-control study performed between September 2021 and March 2022 in the Pediatric Nephrology Units of IU- Cerrahpaşa School of Medicine, Memorial Hospital, Marmara University School of Medicine, IU- Istanbul School of Medicine, Medeniyet University School of Medicine, and Istinye University School of Medicine. The control group has consisted of age and gender comparable 19 healthy children without any acute infection or chronic disease, who were admitted to Cerrahpasa School of Medicine, Pediatric out-patient unit for routine control. When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment. The SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®) administered to all participants by intramuscular route in the deltoid region. At least one month after the second dose of the vaccine, serum samples and whole blood samples were collected from all patients and controls, to analyze the humoral and cellular immune response to the vaccine. All samples were stored at -20 ◦C until testing. SARS-CoV-2 PCR test results were recorded retrospectively to determine natural infection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05465863
Study type Interventional
Source Istanbul University-Cerrahpasa
Contact
Status Completed
Phase N/A
Start date September 1, 2021
Completion date March 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT06126016 - A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.
Not yet recruiting NCT05234047 - Study Evaluating Denosumab on Vascular and Bone Metabolism in Osteoporotic Chronic Kidney Disease (HDENOBS)
Completed NCT04805632 - Immune Response in Dialysis Patients Vaccinated Against COVID-19
Completed NCT05729126 - The Discrepancy in Radiologists' Practice of Intravenous Contrast Imaging Studies Among Chronic Kidney Disease Patients
Completed NCT06394986 - Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction
Recruiting NCT05071131 - Effect of Inulin on Gut Microbiota and Gut Barrier in Chronic Kidney Disease N/A
Recruiting NCT05549154 - A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation N/A
Not yet recruiting NCT06381076 - Examining the Impact of High-protein Oral Supplement With Liposomal Curcumin on Inflammation Markers and Oxidative Stress in Adults Undergoing Hemodialysis. N/A
Recruiting NCT05805813 - Cross-control Study on the Effect of Peritoneal Rest on Peritoneal Transport Function in Peritoneal Dialysis Patients N/A
Recruiting NCT05339009 - Bio-ADM as a Biomarker of Refilling in Chronic Hemodialysis Patient